Ujjivan Small Finance Bank posted a massive 199.9% jump in Q2FY27 net profit to Rs 365 crore. The bank also received board approval for a Rs 409 crore preferential capital raise, bolstering its growth plans while improving asset quality with GNPA dropping to 2.1%.
Ujjivan Small Finance Bank Posts Q2 Net Profit of Rs 365 Cr
Net Interest Income rose 35.4% YoY to Rs 1,248 Cr, while total disbursements grew 32.3% to Rs 10,496 Cr.
Reader Takeaway: Strong operational growth and improved asset quality drive confidence, though margin pressure remains a key watch point.
What just happened
Ujjivan Small Finance Bank (UJSFB) delivered a robust financial performance for the second quarter of FY27. The bank reported a net profit of Rs 365 crore, a sharp 199.9% increase compared to the same period last year. Operating profit (PPOP) stood at Rs 594 crore, reflecting a 50.2% year-on-year growth. The bank also secured board approval to raise Rs 409 crore through a preferential issue, a move aimed at strengthening its capital adequacy.
Why this matters
This growth indicates a successful shift toward a more diversified loan book. The share of secured portfolios has climbed to 52.1%, reducing the bank's reliance on unsecured MFI lending. Simultaneously, asset quality has seen marked improvement, with Gross NPA falling to 2.1% from 2.45% a year ago, signaling better risk management during a phase of rapid disbursement expansion.
Management Commentary and Guidance
The bank remains focused on a 12-14% growth target for its MFI segment in FY27. While management anticipates a minor 10bps pressure on Net Interest Margins (NIM) in the second half of the year due to interest rate cycles, they plan to offset this through increased direct assignment transactions. Additionally, operational efficiency is improving, with the opex-to-total assets ratio projected to settle at 6.2%, lower than earlier estimates.
Risks to watch
Investors should monitor two key areas: the ongoing transition of leadership and potential regulatory shifts. The search for a new MD & CEO is currently underway with a completion timeline of 3-4 months. Furthermore, a pending IRDAI consultation paper on insurance distribution could impact fee-based income, given that nearly half of the bank's insurance revenue in the first half of the year was linked to credit-life products.
What to track next
The market will closely watch the successful completion of the Rs 409 crore capital raise and the subsequent appointment of the new MD & CEO. Tracking the bank’s ability to defend NIMs during the upcoming quarters will also be critical for sustaining current growth trajectories.
